Immunosuppressors and immunomodulators in Neurology - Part I: A guide for management of patients under immunotherapy

Citations of this article
Mendeley users who have this article in their library.


For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.




Abrantes, F. F., De Moraes, M. P. M., De Albuquerque Filho, J. M. V., Alencar, J. M. D., Lopes, A. B., De Rezende Pinto, W. B. V., … Barsottini, O. G. P. (2021, November 1). Immunosuppressors and immunomodulators in Neurology - Part I: A guide for management of patients under immunotherapy. Arquivos de Neuro-Psiquiatria. Associacao Arquivos de Neuro-Psiquiatria.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free